Abstract
Since the emergence of the omicron (B.1.1.529) variant of SARS-CoV-2, the burden of COVID-19 disease on health care has decreased, with rates of hospitalisation due to COVID-19 being substantially reduced despite the increased transmissibility of the omicron variant.1 However, caution might still be warranted for patients with immune-mediated inflammatory diseases, because some immunosuppressants used for treatment of these patients have been shown to reduce humoral or cellar immune responses to SARS-CoV-2 vaccination.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
